Ann Dermatol.  2013 Nov;25(4):500-502. 10.5021/ad.2013.25.4.500.

Lichenoid Drug Eruption after Low-Dose Imatinib Mesylate Treatment

• Lee JH
• Chung JY
• Jung MY
• Kim CR
• Park JH
• Park JH
• Lee JH
• Lee JH
• Yang JM
• Lee DY

• KMID: 2265073
• DOI: http://doi.org/10.5021/ad.2013.25.4.500

Abstract

No abstract available.

MeSH Terms

Benzamides
Drug Eruptions*
Mesylates*
Piperazines
Pyrimidines
Imatinib Mesylate
Benzamides
Mesylates
Piperazines
Pyrimidines

Figure

• 

  Fig. 1 (A) Symmetrically involved erythematous to violaceous papules and plaques, covered extensive body surface area. (B) Slightly elevated violaceous papules and plaque on the right thigh.

• 

  Fig. 2 Histopathological findings. (A) Dense band like lymphocytic infiltration in the upper dermis and deep dermal lymphocytic infiltration (H&E, ×40). (B) Lichenoid lymphocytic infiltration with 'saw-toothed' rete ridges and vacuolar degeneration of the cells in the basal layer. Cytoid bodies in the granular layer (H&E, ×100).

Reference

1. Kawakami T, Kawanabe T, Soma Y. Cutaneous lichenoid eruption caused by imatinib mesylate in a Japanese patient with chronic myeloid leukaemia. Acta Derm Venereol. 2009; 89:325–326.

2. Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther. 2011; 24:386–395.

3. Dalmau J, Peramiquel L, Puig L, Fernández-Figueras MT, Roé E, Alomar A. Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect. Br J Dermatol. 2006; 154:1213–1216.

4. Yang JH, Shin JW, Kim HD, Park YL, Lee SY, Whang KU. Imatinib mesylate (Gleevec(TM))-induced lichenoid drug eruption improved by tentative dose-reduction and topical steroid. Korean J Dermatol. 2011; 49:155–158.

5. Ugurel S, Hildenbrand R, Dippel E, Hochhaus A, Schadendorf D. Dose-dependent severe cutaneous reactions to imatinib. Br J Cancer. 2003; 88:1157–1159.